GleamWall
中文EN

EPRX EUPRAXIA PHARMACEUTICALS INC. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1581178 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-51.3%
TTM EPS YoY-35.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.8%
ROA-63.7%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio15.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$21.33M$16.08M
SG&A expense$17.10M$10.92M
Interest expense$0$603,573
Pretax income-$38.59M-$25.74M
Income tax$19,091$1,804
Net income-$38.58M-$25.50M
EPS (basic)-1.03-0.76
EPS (diluted)-1.03-0.76
Weighted avg. shares (diluted)39.96M33.93M
Balance sheet
Cash & equivalents$80.56M$33.10M
Receivables$716,095$258,074
Current assets$85.10M$34.44M
PP&E, net$834,429$357,893
Total assets$86.15M$34.94M
Current liabilities$5.63M$3.10M
Total liabilities$5.70M$3.10M
Shareholders' equity$82.04M$33.40M
Shares outstanding51.94M35.64M
Cash flow statement
Operating cash flow-$28.55M-$29.99M
Investing cash flow-$588,947-$75,159
Financing cash flow$76.06M$45.78M
Depreciation & amortization$237,717$171,719
Stock-based compensation$8.76M$3.22M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.